J&J, Roche Data Show Dosing Benefit In Treating Anemia With Procrit, Mircera
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J releases data for the first time on treatment of hemoglobin levels with Procrit every two weeks.
You may also be interested in...
Hospira, Stada Collaboration To Yield Biosimilar EPO In The EU Ahead Of U.S.
Hospira obtains exclusive distribution rights for Bioceuticals erythropoietin in the EU and will be solely responsible for U.S. development.
Hospira, Stada Collaboration To Yield Biosimilar EPO In The EU Ahead Of U.S.
Hospira obtains exclusive distribution rights for Bioceuticals erythropoietin in the EU and will be solely responsible for U.S. development.
Epoetin Alfa Increases Cardiovascular Risks When Targeting High Hemoglobin Levels, J&J Study Finds
Patients with chronic kidney disease, when treated with a more aggressive dose of Procrit, had a higher risk but no incremental improvement in quality of life.